Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Chua, Hui W ^a   Ng, Daniel ^b   Choo, Serena ^b   Lum, San S ^a   Li, Huihua ^a   Soh, Li Y ^a   Sabapathy, Kanaga ^a,b,c   Seow, Adeline ^b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE; PROLINE; PROTEIN MDM2; PROTEIN P53; THYMIDINE; MDM2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CHINESE; CODON; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; ONSET AGE; OVERALL SURVIVAL; PROGNOSIS; SINGAPORE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; AGED; CASE CONTROL STUDY; CHINA; ETHNOLOGY; GENETICS; LUNG TUMOR; MIDDLE AGED; MORTALITY; RISK;

AGED; CASE-CONTROL STUDIES; CHINA; CODON; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; RISK; SINGAPORE; SMOKING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77949476980     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-88     Document Type: Article

References (33)

1. Robles AI, Linke SP, Harris CC. The p53 network in lung carcinogenesis. Oncogene 2002, 21:6898-907. 10.1038/sj.onc.1205563, 12362272.
2. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387:296-9. 10.1038/387296a0, 9153395.
3. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602. 10.1016/j.cell.2004.11.022, 15550242.
4. Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 2005, 65:5481-4. 10.1158/0008-5472.CAN-05-0825, 15994915.
5. Mittelstrass K, Sauter W, Rosenberger A, Illig T, Timofeeva M, Klopp N, Dienemann H, Meese E, Sybrecht G, Woelke G, Cebulla M, Degen M, et al. Early onset lung cancer, cigarette smoking and the SNP309 of the murine double minute-2 (MDM2) gene. BMC Cancer 2008, 8:113. 10.1186/1471-2407-8-113, 2377274, 18433484.
6. Liu G, Wheatley-Price P, Zhou W, Park S, Heist RS, Asomaning K, Wain JC, Lynch TJ, Su L, Christiani DC. Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk. Int J Cancer 2008, 122:915-8. 10.1002/ijc.23178, 17957785.
7. Pine SR, Mechanic LE, Bowman ED, Welsh JA, Chanock SC, Shields PG, Harris CC. MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006, 15:1559-61. 10.1158/1055-9965.EPI-06-0217, 16896050.
8. Hu Z, Ma H, Lu D, Qian J, Zhou J, Chen Y, Xu L, Wang X, Wei Q, Shen H. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer 2006, 118:1275-8. 10.1002/ijc.21463, 16152608.
9. Park SH, Choi JE, Kim EJ, Jang JS, Han HS, Lee WK, Kang YM, Park JY. MDM2 309T>G polymorphism and risk of lung cancer in a Korean population. Lung Cancer 2006, 54:19-24. 10.1016/j.lungcan.2006.06.008, 16876289.
10. Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, Wang Y, Lin D. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 2006, 27:110-7. 10.1002/humu.20277, 16287156.
11. Lind H, Zienolddiny S, Ekstrøm PO, Skaug V, Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 2006, 119:718-21. 10.1002/ijc.21872, 16496380.
12. Li G, Zhai X, Zhang Z, Chamberlain RM, Spitz MR, Wei Q. MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis 2006, 27:2028-33. 10.1093/carcin/bgl047, 16675470.
13. Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 2007, 28:2262-7. 10.1093/carcin/bgm191, 17827408.
14. Han JY, Lee GK, Jang DH, Lee SY, Lee JS. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 2008, 113:799-807. 10.1002/cncr.23668, 18618574.
15. Heist RS, Zhou W, Chirieac LR, Cogan-Drew T, Liu G, Su L, Neuberg D, Lynch TJ, Wain JC, Christiani DC. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J Clin Oncol 2007, 25:2243-7. 10.1200/JCO.2006.08.8914, 17538168.
16. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987, 7:961-3. 365159, 3547088.
17. Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S, Saisho H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis 1996, 17:261-4. 10.1093/carcin/17.2.261, 8625447.
18. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF, Spitz MR. p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. J Natl Cancer Inst 2002, 94:681-90.
19. Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 2003, 18:377-85. 10.1093/mutage/geg008, 12840112.
20. Nelson HH, Wilkojmen M, Marsit CJ, Kelsey KT. TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis 2005, 26:1770-3. 10.1093/carcin/bgi125, 15905205.
21. Wang YC, Chen CY, Chen SK, Chang YY, Lin P. p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 1999, 5:129-34.
22. Szymanowska A, Jassem E, Dziadziuszko R, Borg A, Limon J, Kobierska-Gulida G, Rzyman W, Jassem J. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer 2006, 52:9-14. 10.1016/j.lungcan.2005.12.007, 16499995.
23. Lind H, Ekstrom H, Ryberg PO, Skaug V, Andreassen T, Stangeland L, Haugen A, Zienolddiny S. Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer. Cancer Epidem Biom Prev 2007, 16:2077-81.
24. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol 2007, 25:561-70. 10.1200/JCO.2006.06.8015, 17290066.
25. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers--a different disease. Nat Rev Cancer 2007, 7:778-90. 10.1038/nrc2190, 17882278.
26. Lum SS, Chua HW, Li H, Li WF, Rao N, Wei J, Shao Z, Sabapathy K. MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis 2008, 29:754-61. 10.1093/carcin/bgn024, 18281248.
27. Seow A, Poh WT, Teh M, Eng P, Wang YT, Tan WC, Yu MC, Lee HP. Fumes from meat cooking and lung cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 2000, 9:1215-21.
28. Phang BH, Linn YC, Li H, Sabapathy K. MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur J Cancer 2008, 44:760-6. 10.1016/j.ejca.2008.02.007, 18313915.
29. Kinyamu HK, Archer TK. Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression. Mol Cell Biol 2003, 23:5867-81. 10.1128/MCB.23.16.5867-5881.2003, 166332, 12897156.
30. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006, 66:5104-10. 10.1158/0008-5472.CAN-06-0180, 16707433.
31. Duong V, Boulle N, Daujat S, Chauvet J, Bonnet S, Neel H, Cavailles V. Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Res 2007, 67:5513-21. 10.1158/0008-5472.CAN-07-0967, 17545634.
32. Omoto Y, Kobayashi Y, Nishida K, Tsuchiya E, Eguchi H, Nakagawa K, Ishikawa Y, Yamori T, Iwase H, Fujii Y, Warner M, Gustafsson JA, et al. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 2001, 285:340-7. 10.1006/bbrc.2001.5158, 11444848.
33. Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, Finkelstein S, Siegfried JM. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 2002, 62:2141-50.